GoalBMI Wellness
Tesamorelin Before & After Results: Week-by-Week & Month-by-Month Timeline
Tesamorelin Peptide Therapy · New York
The Trial Data Behind Every Stage of Treatment
What the pivotal FDA trials showed week by week and month by month — one of the few peptide timelines backed by real Phase 3 data.
Written by Karla K. Mioduchoski, FNP-BC
|
Medically Reviewed by Dr. Rosemary Daly, D.O.
|
Updated for New York patients
Contents
Unlike most peptides, tesamorelin’s timeline isn’t guesswork — it comes from two completed Phase 3 clinical trials involving 816 patients. This page walks through what the trial data showed at each stage, from the first weeks of treatment through two years of continued use, while being clear that individual results vary and any specific outcome depends on your own health profile.
“What I like about tesamorelin is that we’re not just estimating a timeline — we have real trial data showing when changes were measurable. That gives patients something concrete to expect.”
— Karla K. Mioduchoski, FNP-BC
Week by Week
The early weeks
Week 1
Starting the Program
Focus is on injection technique and reconstitution routine. No measurable body composition change is expected yet.
Week 2
Adjustment Period
Some patients notice mild injection-site reactions or joint discomfort as the body adjusts. This is the window most side effects, if they occur, tend to appear.
Week 3
Establishing Routine
Most patients have settled into a consistent injection schedule by this point.
Week 4
One Month In
Growth hormone and IGF-1 levels are typically checked around this point to confirm the expected physiological response.
Month by Month
What the pivotal trials measured
Month 2
Early Trends Emerge
Some patients in the pivotal trials began showing early trends in visceral fat measures, though the primary endpoint was assessed later.
Month 3
Approaching the Primary Endpoint
The pivotal trials’ primary measurement point was 26 weeks (roughly six months) — this is when the clearest data exists.
Month 6 (26 Weeks)
Primary Trial Endpoint — 18% Average Reduction
In the pivotal Phase 3 trials, patients showed an average 18% reduction in visceral adipose tissue at this point — the data point the FDA approval is based on.
Long-Term (104 Weeks)
Sustained With Continued Treatment
Extension trial data through two years showed the reduction was sustained as long as treatment continued — reinforcing that tesamorelin works as an ongoing therapy, not a one-time intervention.
An Important Finding
What happens if treatment stops
From the original trial design: When the regulatory study required patients to discontinue tesamorelin at 52 weeks, visceral fat generally returned within a few months. This is a meaningful data point — it indicates that tesamorelin’s benefits are tied to continued treatment, similar to how many growth hormone-axis therapies work. Discuss with your provider what a realistic long-term plan looks like before starting.
Compounded Formulations
Compounded Tesamorelin Before and After Results
Patients may also search for before-and-after results with compounded tesamorelin. However, compounded tesamorelin is not FDA-approved and should not be assumed to produce the same results or follow the same timeline reported in clinical trials of FDA-approved tesamorelin.
The clinical trial results discussed on this page come from studied tesamorelin in patients with HIV-associated lipodystrophy. If you are prescribed compounded tesamorelin, your provider should discuss realistic expectations, monitoring, and follow-up based on your individual treatment plan and the formulation dispensed by your pharmacy.
Important: Formulation and concentration may vary by compounding pharmacy. Do not use another patient’s timeline, vial concentration, or before-and-after results to guide your own treatment.
What Actually Matters
Factors that affect individual results
Biology
Baseline GH levels
Starting hormone levels influence how someone responds to GHRH-analog therapy.
Consistency
Adherence to schedule
The clinical trial results reflect consistent use — missed doses may affect outcomes.
Health status
Underlying condition
Results in the approved population (HIV-associated lipodystrophy) may not directly predict off-label use outcomes.
“I always tell patients: the 18% figure is a trial average, not a guarantee for any one person. Some patients respond more, some less. What we can promise is close monitoring and an honest conversation at every follow-up.”
— Dr. Rosemary Daly, D.O.
Answers
Frequently asked questions about the tesamorelin timeline
The pivotal clinical trials measured their primary result at 26 weeks (about six months), showing an average 18% reduction in visceral adipose tissue. Some patients may notice earlier changes, but the trial data is clearest at this six-month mark.
Trial data suggests not without continued treatment. When patients discontinued after 52 weeks in the original study design, visceral fat generally returned within a few months — indicating ongoing use is likely needed to maintain results.
No. That figure is a clinical trial average across 816 patients with HIV-associated lipodystrophy specifically. Individual results vary based on health status, adherence, and other factors — no specific outcome can be promised.
The clinical trial timeline reflects patients with HIV-associated lipodystrophy specifically, the approved indication. For off-label use, outcomes and timelines are less well established — discuss realistic expectations with your provider.
No specific timeline or result should be assumed. Compounded tesamorelin is not FDA-approved and has not been evaluated through the same approval process as EGRIFTA®. Results can vary based on formulation, prescribed treatment plan, health history, and individual response.
📚 Continue Learning About Tesamorelin
Discuss a realistic timeline with your provider
A licensed New York provider can walk you through what a realistic timeline may look like for your specific situation.
⚠️ Medical & Educational Disclaimer: Tesamorelin (brand names Egrifta® / Egrifta WR®) is FDA-approved specifically for the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. Use for general visceral fat or metabolic wellness goals outside this approved indication is off-label and is determined individually by a licensed provider following evaluation. Nothing on this page is a promise of specific results. Always follow the exact instructions of your prescribing provider. Peptide therapy is available only to eligible patients in states where our providers are licensed. In a medical emergency, call 911.